The purpose of this work was to formulate enteric-coated tablets of Rabeprazole sodium for ulcer therapy. Tablets can be prepared by using commonly approved excipients, which were proved compatible with the active ingredient by DSC and physical observation, method adopted was wet granulation. Excipients used were mannitol, crossprovidole as super disintegrant. Compressed core tablets were given seal coat using HPC followed by enteric coat using HPMCP. Core tablets were checked for parameters like hardness, thickness, friability, disintegration time, and drug content. The tablets were evaluated for disintegration time and drug content. Dissolution studies of the tablets were also carried out using USP (type 2) dissolution apparatus. The dissolution media of OGD Media, 6.0 pH phosphate buffer and 6.8 pH phosphate buffer solution were used at 37° ± 0.5° C for 30 mins in followed by 45 minutes in 6.8 pH Phosphate buffer solution AND 6.0 pH phosphate buffer. Based on the tablets evaluation results, some formulations were selected as the best formulations and were tested for stability studies and evaluated.
Cite this article:
Viral Patel. Design, Development, Evaluation and Optimization of Antiulcer Delayed Release Tablets. Research J. Pharm. and Tech 6(6): June 2013; Page 669-684.
Viral Patel. Design, Development, Evaluation and Optimization of Antiulcer Delayed Release Tablets. Research J. Pharm. and Tech 6(6): June 2013; Page 669-684. Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2013-6-6-9